Brief: Disc Reports Topline Results From Phase 2 AURORA Study Of Bitopertin In Patients With Erythropoietic Protoporphyria

Disc Medicine

01/04/2024 13:52

April 1 (Reuters) - Disc Medicine Inc  IRON.O :
    * DISC MEDICINE INC - MET PRIMARY ENDPOINT
    * DISC MEDICINE INC: DID NOT MEET STATISTICAL SIGNIFICANCE
COMPARED TO PLACEBO
    * DISC REPORTS TOPLINE RESULTS FROM PHASE 2 AURORA STUDY OF
BITOPERTIN IN PATIENTS WITH ERYTHROPOIETIC PROTOPORPHYRIA (EPP)

Source text for Eikon:  ID:nGNX7BkzXQ 
Further company coverage:  IRON.O 

 ((Reuters.Briefs@thomsonreuters.com;))